Form 4: Incyte Corp: Executive Stock Awards and Option Grants

Incyte Corp executive Suketu Upadhyay reports on stock awards, restricted stock units, and stock options granted on May 4, 2026.

Summary

• Suketu Upadhyay, EVP & Chief Financial Officer of Incyte Corp, has reported transactions related to his beneficial ownership of company stock.
• On May 4, 2026, Mr. Upadhyay received an award of 26,343 restricted stock units (RSUs). These RSUs will vest 25% annually over four years and can be settled for common stock on a one-for-one basis.
• Additionally, on the same date, Mr. Upadhyay was granted employee stock options to purchase 38,429 shares of common stock at an exercise price of $97.14 per share. These options become exercisable in installments, with 25% vesting after one year and the remainder vesting monthly over three years, expiring on May 4, 2036.
• The filing also notes an award of 13,171 performance shares on May 4, 2026, which may result in the receipt of up to 200% of one share of common stock per performance share based on the company's relative total shareholder return (TSR) over a three-year period starting January 1, 2026. These earned shares will vest on the third anniversary of the grant date, subject to continued service.
• Following these transactions, Mr. Upadhyay beneficially owns 26,343 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports on standard executive compensation awards rather than significant financial performance or strategic shifts.

Positives

• Grant of restricted stock units (RSUs) indicates a long-term incentive for the executive, aligning their interests with shareholders.
• Award of performance shares suggests a focus on achieving specific performance metrics (TSR) tied to shareholder value.
• Vesting schedules for RSUs and stock options encourage executive retention and long-term commitment to the company.

Negatives

• The filing details stock awards and options, which represent potential future dilution for existing shareholders if exercised or vested.
• The exercise price of stock options ($97.14) is noted, but the current market price is not provided, making it difficult to assess immediate value.

Risks

• Performance shares are contingent on the company's relative total shareholder return (TSR) compared to a peer group, introducing performance-based risk.
• Vesting of RSUs and stock options is subject to the reporting person's continued service with the issuer, meaning departure before vesting results in forfeiture.

Future Outlook

The filing primarily details past transactions (grants on May 4, 2026) and future vesting/expiration dates for these awards. It does not contain explicit forward-looking financial guidance or projections from the company.

Management Comments

• The filing is a statement of changes in beneficial ownership and does not contain direct quotes or paraphrased statements from management regarding strategy or performance.

Industry Context

StockSavvy.ai notes that the issuance of stock options, RSUs, and performance shares is a common practice in the biopharmaceutical industry to attract, retain, and incentivize key executives. These awards are typically tied to company performance and long-term value creation.

Stakeholder Impact

• Shareholders: Potential for future dilution if stock options are exercised or RSUs vest. Alignment of executive interests with long-term shareholder value creation through performance-based awards.
• Employees: The executive's compensation structure may influence overall company compensation philosophy.
• Management: Reinforces the incentive structure for key executives to drive company performance.

Next Steps

• Vesting of 25% of RSUs on May 4, 2027.
• Vesting of 25% of stock options on May 4, 2027.
• Continued vesting of RSUs and stock options over the subsequent years.
• Performance assessment for performance shares over the three-year period ending in 2029.
• Vesting of earned performance shares on May 4, 2029.

Key Dates

Keywords

Incyte Corp, Form 4, SEC Filing, Stock Options, Restricted Stock Units, Performance Shares, Executive Compensation, Insider Trading, Beneficial Ownership, Suketu Upadhyay